Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
Volume 1.85M
Average 5.09M
HOWL EBITDA Margin
EBITDA as a percentage of revenue.
Werewolf Therapeutics, Inc.NASDAQ: HOWL
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin at 52.3%
EBITDA Margin was 52.3% in Q2 FY2026. On a trailing-twelve-month basis it was -104.8%.
Context
- EBITDA Margin widened in 1 of the last 2 fiscal years.
- FY2024 was the lowest level in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2024
- -3397.6%
- Year-over-year change
- -3234.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | — | — |
| FY2024 | 2024-12-31 | -3397.6% | -3234.8pp |
| FY2023 | 2023-12-31 | -162.8% | +158.6pp |
| FY2022 | 2022-12-31 | -321.4% | — |
| FY2021 | 2021-12-31 | — | — |
EBITDA Margin vs competitors
How HOWL compares with its peers on the latest reported figures
- HOWL's LTM Jun 2026 EBITDA Margin of -104.8% is the 2nd highest of the 5 companies compared; the peer median is -9825.8%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -48.4% | +416.8 pp | +3974.4 pp | |
| LTM Jun 2026 | -104.8% | — | — | |
| LTM Mar 2026 | -1017.5% | — | — | |
| LTM Mar 2026 | -18634.1% | -28166.9 pp | — | |
| FY2025 | -91698.0% | +204937.7 pp | -91337.6 pp | |
| FY2025 | — | — | — | |
OSTXOS Therapies Incorporated | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding HOWL) | -9825.8% | +416.8 pp | -43681.6 pp | |
Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 16.4M | 19.94M | 1.89M | 0 |
| Cost of Revenue | 0 | 2.51M | 1.76M | 1.81M | 1.63M |
| Gross Profit | 0 | 13.89M | 18.18M | 71K | (1.63M) |
| Gross Margin | — | 84.7% | 91.2% | 3.8% | — |
| Research & Development | 35.27M | 53.76M | 41.78M | 56.43M | 44.83M |
| Selling, General & Admin | 14.82M | 21.5M | 18.67M | 19.05M | 15.85M |
| Operating Expenses | 50.09M | 69.95M | 58.68M | 73.67M | 59.04M |
| Depreciation & Amortization | 216K | 1.1M | 1.76M | 1.81M | 1.63M |
| EBITDA | (49.77M) | (52.71M) | (32.47M) | (64.05M) | (53.91M) |
| EBITDA Margin | — | -321.4% | -162.8% | -3397.6% | — |
| Operating Income | (50.09M) | (56.06M) | (40.5M) | (73.59M) | (60.68M) |
| Operating Margin | — | -341.8% | -203.1% | -3904.2% | — |
| Interest Income | 104K | 1.91M | 7.42M | 6.67M | 3.11M |
| Interest Expense | 0 | 0 | 3.14M | 4.66M | 5.27M |
| Other Income / Expenses | 104K | 2.25M | 3.14M | 3.08M | (145K) |
| Income Before Tax | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Pre-Tax Margin | — | -328.1% | -187.4% | -3740.8% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Net Margin | — | -328.1% | -187.4% | -3740.8% | — |
| EPS (Basic) | (10.94) | (1.86) | (1.05) | (1.63) | (1.32) |
| EPS (Diluted) | (10.94) | (1.86) | (1.05) | (1.63) | (1.33) |
| Weighted Avg Shares | 18.46M | 28.86M | 35.65M | 43.33M | 46.02M |
| Weighted Avg Shares (Diluted) | 18.46M | 28.86M | 35.65M | 43.86M | 46.81M |
Werewolf Therapeutics, Inc.
NASDAQ:HOWL
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.